Entering text into the input field will update the search result below

Cell Therapeutics says preclinical study shows Pixuvri is novel and distinct

Oct. 21, 2013 8:16 AM ETCTI BioPharma Corp. (CTIC) StockCTICBy: Colin Lokey, SA News Editor
  • Cell Therapeutics (NASDAQ:CTIC) says a preclinical study suggests Pixuvri's "mechanism of inducing tumor cell death is novel and distinct from that of anthracyclines such as doxorubicin."
  • Here's Dr. Neil Beeharry putting it In simpler terms: "The study results suggest that Pixuvri ... is the first approved drug in a new class of anti-cancer agents."
  • Pixuvri is approved in the EU for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
  • CTIC +2.7% premarket

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
CTIC--
CTI BioPharma Corp.